KEGG   DRUG: Fulvestrant
Entry
D01161                      Drug                                   
Name
Fulvestrant (JAN/USP/INN);
Faslodex (TN)
Product
FASLODEX (AstraZeneca Pharmaceuticals LP), FULVESTRANT (Fresenius Kabi USA)
  Generic
FULVESTRANT (Accord Healthcare), FULVESTRANT (Alembic Pharmaceuticals), FULVESTRANT (Amneal Pharmaceuticals LLC), FULVESTRANT (Athenex Pharmaceutical Division), FULVESTRANT (Avenacy), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (BluePoint Laboratories), FULVESTRANT (BluePoint Laboratories.), FULVESTRANT (Chia Tai Tianqing Pharmaceutical Group), FULVESTRANT (Dr.Reddy's Laboratories), FULVESTRANT (Eugia US LLC), FULVESTRANT (Hikma Pharmaceuticals USA), FULVESTRANT (Meitheal Pharmaceuticals), FULVESTRANT (Northstar Rx), FULVESTRANT (Sagent Pharmaceuticals), FULVESTRANT (Sandoz), FULVESTRANT (Sandoz), FULVESTRANT (Xiromed), FULVESTRANT (Zydus Lifesciences Limited), FULVESTRANT (Zydus Pharmaceuticals USA)
Formula
C32H47F5O3S
Exact mass
606.3166
Mol weight
606.77
Structure
Class
Antineoplastic
 DG01585  Estrogen receptor antagonist
Hormonal agent
 DG01619  Estrogen receptor antagonist/modulator
  DG01621  Selective estrogen receptor modulator
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 4291
ATC code: L02BA03
Product: D01161<JP/US>
Efficacy
Antineoplastic, Estrogen receptor agonist/antagonist
  Disease
Breast cancer, postmenopausal (HR positive) [DS:H00031]
Breast cancer, postmenopausal (HR positive, HER2 negative) [DS:H00031]
Target
NR3A (ESR) [HSA:2099 2100] [KO:K08550 K08551]
  Pathway
hsa04915  Estrogen signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Structure map
map07043  Antineoplastics - hormones
map07226  Progesterone, androgen and estrogen receptor agonists/antagonists
Other map
map01522  Endocrine resistance
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L02 ENDOCRINE THERAPY
   L02B HORMONE ANTAGONISTS AND RELATED AGENTS
    L02BA Anti-estrogens
     L02BA03 Fulvestrant
      D01161  Fulvestrant (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antiestrogens/Modifiers
   Estrogen Agonists/ Antagonists
    Fulvestrant
     D01161  Fulvestrant (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D01161  Fulvestrant (JAN/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01585  Estrogen receptor antagonist
   D01161  Fulvestrant
 Hormonal agent
  DG01619  Estrogen receptor antagonist/modulator
   DG01621  Selective estrogen receptor modulator
    D01161  Fulvestrant
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D01161  Fulvestrant
Drug classes [BR:br08332]
 Antineoplastic
  DG01585  Estrogen receptor antagonist
   D01161  Fulvestrant
Target-based classification of drugs [BR:br08310]
 Nuclear receptors
  Estrogen like receptors
   Estrogen receptor
    NR3A (ESR)
     D01161  Fulvestrant (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D01161
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D01161
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D01161
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D01161
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D01161
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D01161
Other DBs
CAS: 129453-61-8
PubChem: 7848224
ChEBI: 31638
PDB-CCD: FVS[PDBj]
LigandBox: D01161
NIKKAJI: J401.163E
LinkDB
KCF data

ATOM        41
            1   C8x C     7.4203  -16.5528
            2   C8y C     7.4203  -17.9330
            3   C8x C     8.6185  -18.6231
            4   C8x C     8.6185  -15.8628
            5   C8y C     9.8096  -16.5528
            6   C8y C     9.8037  -17.9330
            7   C1x C    10.9960  -18.6281
            8   C1y C    12.1942  -17.9432
            9   C1y C    11.0077  -15.8679
            10  C1y C    12.1942  -16.5658
            11  C1x C    12.2169  -13.8129
            12  C1x C    11.0191  -14.4913
            13  C1z C    13.4035  -14.5109
            14  C1y C    13.3866  -15.8831
            15  C1x C    15.7638  -15.9121
            16  C1x C    15.7803  -14.5396
            17  C1y C    14.6003  -13.8392
            18  O1a O    14.7331  -12.4541
            19  O1a O     6.2253  -18.6237
            20  C1b C    13.3801  -18.6301
            21  C1b C    14.5721  -17.9469
            22  C1b C    15.7641  -18.6370
            23  C1b C    16.9561  -17.9539
            24  C1b C    18.1480  -18.6440
            25  C1b C    19.3400  -17.9609
            26  C1b C    20.5319  -18.6510
            27  C1b C    21.7239  -17.9678
            28  C1b C    22.9159  -18.6579
            29  S4a S    24.1078  -17.9748
            30  C1b C    25.2998  -18.6649
            31  C1b C    26.4917  -17.9819
            32  C1b C    27.6837  -18.6720
            33  C1d C    28.8756  -17.9887
            34  O3c O    24.1108  -16.5946
            35  X   F    29.9914  -17.2156
            36  X   F    27.8928  -17.0058
            37  C1a C    13.3941  -13.1303
            38  C1d C    29.8649  -18.9778
            39  X   F    30.8541  -19.9671
            40  X   F    31.0764  -18.2784
            41  X   F    28.6534  -19.6773
BOND        44
            1     4   1 1
            2     2  19 1
            3     1   2 2
            4     8  20 1 #Down
            5     9  10 1
            6    20  21 1
            7    10  14 1
            8    21  22 1
            9    13  11 1
            10   22  23 1
            11   11  12 1
            12   23  24 1
            13   12   9 1
            14   24  25 1
            15    2   3 1
            16   25  26 1
            17    3   6 2
            18   26  27 1
            19    5   6 1
            20   27  28 1
            21    6   7 1
            22   28  29 1
            23    7   8 1
            24   29  30 1
            25   13  14 1
            26   30  31 1
            27   15  16 1
            28   31  32 1
            29   16  17 1
            30   32  33 1
            31   17  13 1
            32   29  34 2
            33   14  15 1
            34    8  10 1
            35   17  18 1 #Up
            36    9   5 1
            37   33  35 1
            38    5   4 2
            39   33  36 1
            40   13  37 1 #Up
            41   33  38 1
            42   38  39 1
            43   38  40 1
            44   38  41 1

» Japanese version   » Back

DBGET integrated database retrieval system